Digital Biomarkers: Translating New Digital Data Sources Into Clinical Insights To Enhance Drug Development (Healthcare Sensor Innovations 2019)

The rapid evolution of sensors and mobile devices for the collection of health-related data is laying the foundation for the next revolution in clinical drug development. These technologies not only provide the ability to measure much more detailed disease phenotypes than conventional clinical methods but also provide the ability to follow patients longitudinally with much higher frequency than is possible through traditional clinical examination. In this presentation I will explain how we go about introducing novel sensors in our clinical studies studies, and the impact that the data we are collecting is expected to make in assessing treatment efficacy and adding value to our patients and medicines.

Dr Luis Garcia-Gancedo is the Director of Digital Biomarkers at GlaxoSmithKline (GSK). With a background in Physics and Electronic Engineering, Luis spent a number of years as a Research Associate in the Engineering Department at the University of Cambridge and as a College Lecturer at Newnham College (University of Cambridge) before joining GSK.

Currently he leads the development of a strategic portfolio of novel digital measures of disease progression (digital biomarkers) to support GSK's pipeline of innovative medicines. This includes pioneering new digital tools and data science approaches to investigate these measurements in our therapeutic clinical studies with the aim to collect 'real-world' data that reflects a reasonable approximation of how study participants usually live their lives, ultimately enabling a better understanding of disease manifestation and a better assessment of drug efficacy.

Luis' long-term mission is to use digital technologies to improve the lives of patients, helping them do more, feel better and live longer.

GlaxoSmithKline (GSK) plc is one of the largest pharmaceutical companies in the world. With headquarters in Brentford, London, GSK has 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.